Healthcare Social Media and Updates
Healthcare Social Media and Updates
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Billionaire-backed scientists aim to grow 'headless humans' to farm their organs... and help biohackers live for longer https://t.co/uQOzEtBapf https://t.co/HYZCMCOPy3
Serum uric acid levels and longitudinal change in cognitive function in older adults: a sex-stratified population-based study https://t.co/vl5LLY6mBc
Public health discourse needs a nomenclature committee before this “peptides” thing gets out of hand. So many types, so much variation in evidence, so much at stake. Common language would really help everyone: pro and against.
On Lex Fridman's podcast this week, Jensen Huang brought up radiology and AI, highlighting radiology as an important data point for how we can expect AI to influence jobs. He talked about how nearly a decade ago, AI researchers predicted...
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/Y1ti72KB2p
This week's @TheLancet cover and editorial about getting GLP-1 drugs available for the people who need them the most https://t.co/BU9NZdmdGo https://t.co/TWOIKvfuth
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/ejA8KSoxOL
Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/lbZ4AFZ1YM
What a joy to chat with my old friend Rob Califf @DrCaliff_FDA about the FDA under his leadership, the FDA today, AI regulation, misinformation, clinical research & more. We also discussed his memories of being a @UCSF medicine resident back...
AI smart glasses win major funding to support dementia care, though real-world effectiveness and long-term impact remain uncertain despite early promising observations. https://t.co/vX7jBV2aJt
Evidence-based clinical intelligence is becoming a critical infrastructure for many healthcare technology companies. We've made building with our clinical AI agent exceptionally easy with in-app self-serve access to the Glass Developer API. Developers can get started building with our AI today and...
What should hospitals consider before adopting a new AI tool? Start simple: will people actually use it? That’s a key takeaway from our panel at #vMed26: “Translating AI Findings into Real-World Clinical Impact.” https://t.co/dTZgscHIOM
A “kazarian?” Is that like a Kardashian? What planet are these X trolls from? I develop low-cost often patent-free vaccines for global health and to help humanity. So far 100 million have benefited from access to our vaccine technologies developed...
@Ronalfa is speaking at @SynBioBeta in May and you probably already know who he is if you've been paying any attention to the AI x bio space. Ron spent years at @RecursionPharma as SVP of Research and acting CSO, helping build...
Most cancer drugs go after the same targets: EGFR. PD-L1. HER2. Not because they’re the best targets. Because they’re the only ones we’ve been able to see. RyboDyn Inc. is going after what’s been invisible. The San Diego team, led by Imad Ajjawi, PhD,...
NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence https://t.co/au5YIC11Hw https://t.co/fMsAOSQF6f
Pleased to join the Scientific Advisory Board at @LifespanRI, an organization dedicated to accelerating research on age-related disease and extending healthy human lifespan. Looking forward to contributing to this important work. 🚀 https://t.co/HSdyrtABCK https://t.co/754TAi6znw
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends https://t.co/20H9OXVtIB $WVE - 54% $KOD + 58%
"A much stronger cancer-preventive potential of obesity prevention and control than previously established" https://t.co/QatHKVMbfz @JAMAOnc https://t.co/OQ62MunGTu
🧵 No one talks about this part of being a doctor. You keep showing up. Even when you’re tired. Even when you don’t feel like it. Even when life outside is falling apart. Because patients don’t see your bad days. They see a doctor. So you hold...
My article in today's issue of the Journal of the American Medical Association Health Forum, on FDA's new rare disease guidance, and how the agency can build on these policy steps to promote innovation for inherited disorders, authored with Maarika...
FDA clears Denali drug in ‘clear step’ for rare disease biotechs https://t.co/x9yL4nyPaj by Kristin Jensen $DNLI #biotech
1 of 4 people have an APOE4 allele, a risk factor for Alzheimer's disease. New evidence this is linked to abnormal meningeal lymphatic function, brain inflammation, and important sex-differences @NeuroCellPress https://t.co/mUUqLedS9V https://t.co/FADCoemvum
One large psilocybin dose beat nicotine patches by 6x odds for smoking cessation. 82 otherwise-healthy cigarette smokers, 42 received a single high-dose 30mg/70kg psilocybin session, and 40 initiated an 8- to 10-week course of nicotine patch treatment. At 6 months; participants were 6x...
Of all the IO companies I've met and covered in the past ~15 years I'm struggling to think of one that's been more disappointing vs its initial promise than $IPHYF. Will it even last beyond Q3? Via @ByMadeleineA -> https://t.co/DepdZfDBdY
This week's Biotech Scorecard: Allogene $ALLO: A preview of its April interim analysis. Very interesting (to me, at least) There just might be a path forward for off-the-shelf CAR-T therapy in B-cell lymphoma. Frontline consolidation. Read all about it: https://t.co/tcPFelUH3C
Harvard’s twistable light chip could give drug developers a new tool for sorting mirror-image molecules https://t.co/WkjjD38exo https://t.co/5kr4d9f6sa
As a medical school professor, I've spent decades writing papers and reviewing studies. Now AI can do it all -- start to finish. Researchers from Sakana AI, Oxford, and UBC just published in Nature: "The AI Scientist" -- a system that...
Over the past four years, alcohol companies have collectively lost $830 billion in market value—with Gen Z emerging as a major driver. U.S. adult drinking rates have dropped to just 54%, the lowest level since tracking began in 1939, This shift comes...
If you use the terminology “GLP-3” instead of GLP-1/GIP/Glucagon receptor agonist or at least triple agonist, I’m going to assume you don’t know much about these medicines.
As a medical school professor, I can tell you: the textbooks got this one wrong. We taught that once you have prostate cancer, exercise is nice but optional. New data says it may be the most powerful tool in your arsenal. 828...
The healthcare model moves to homeownership. Higher premiums for lower coverage. Now let's pause to consider who this adversely impacts the most. I suppose we should take consolation in the fact that those at the bottom were already priced out of home ownership.
Scholar Rock's anti-TGFb1 antibody clinical study with early data in oncology indications... minimal AEs and signs of durable efficacy in checkpoint-refractory patients. $SRRK https://t.co/8xsN4wtbMV
Measles in federal detention facility reaches the Texas public. My comments with @alexnguyen2311 @TexasTribune https://t.co/zaqrcEa4rC
A lot of midlife women are not failing weight loss advice. They are following advice that may be physiologically mismatched to this stage of life. In this episode of The Podcast by KevinMD, Marsha Shepherd Whitt challenges a message clinicians and patients...
Ceiling Rail System Gives Wheelchair Users New Freedom at Home by @SusieM414141 #MedTech #Healthcare #HealthTech #Tech #Technology https://t.co/ckMgvssrGM
Proud of the work of our Seaport team & collaborators published today in @ScienceTM. This ~13 page peer reviewed paper is the first comprehensive data disclosure of our GlyphAllo™ program from discovery through initial human proof‑of‑concept.
So pleased that people like Professor Denis Migliorini @MiglioriniDenis are leading the fight against solid tumors such as GBM / glioblastoma: he is an inspiration. https://t.co/8ohKJG4mQq
Corporations as vectors of chronic disease, @NEJM Calling out 6 commercial products that contribute to 31% of all deaths globally. Chemicals include pesticides, PFAS, manufactured. And counterstrategies to address https://t.co/b6iDYcEyct https://t.co/JYJId8uNyV
When we published our H2H in @NEJM Ian Jordan raised an excellent letter re SSRI discontinuation & how it might impact response. We looked & found he was right. Those who discontinued SSRIs and went back on (escitalopram) did far...
Here it is again. Amazing how researchers could get away with this back then. Regular systematic bias of excluding TAD nonresponders. Also note another thing inconsistent with core psychedelic trial period i.e., that Ps were allowed to continue psychotherapy outside...
When Susan Monarez was fired as #CDC director, the administration knew it has 210 days to nominate a replacement. Today is Day 210 & no nominee. Finding someone who can gain Senate approval & Sec Kennedy's approval may be proving...
"We health professionals must call urgent attention to this silent but deadly assault [EPA dismantling ] on American's health...." @NEJM https://t.co/FJYbZh5O1m https://t.co/hajEmMWHTs
Humanoid robots + AI will mean everyone on Earth has access to better medical care than the richest person alive today. THAT is what abundance looks like.
When people ask "How can we make #AAV #GeneTherapy accessible and affordable" --> this is how 👇
One thing that really makes the in-person summits we run at STAT so amazing: the people in the room. Here's what happened when we asked some of them for the last big breakthrough they saw. Featuring: the infectious @DrBlytheAdamson, genomcis pioneer...
EXCLUSIVE: in a sea of Terminator-looking bots, Aussie founder Grace Brown took a different direction for her robot, Abi: color, bubbles, and fun. Now her startup Andromeda, which has raised $16.6M, is launching for senior homes across the U.S. - with...
No one is going to come save you. That line is the center of this episode of The Podcast by KevinMD, and it lands because it names something many physicians feel but rarely say out loud. Hospice and palliative care physician Sarah...
See this for just 1 of the TAD trials from recent @psybalazs and @QuantPsychiatry comparative analysis. 1 of several deck stacks favoring TADs. This trial reported a surprising -15.2 HAM-D drop with venlafaxine. Not so surprising when you look closer......
